Ledger.

Venture capital fund · 34 deals

OneVentures

Sydney, NSW

Coverage

Stories naming OneVentures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

3 deals

Buildkite quietly raised $21 million earlier this year after posting massive losses

ASIC filings show Buildkite raised $21m via convertible debt in January 2026 after heavy losses and a CEO change; its earlier backers include OneVentures, AirTree, General Catalyst and Dom Pym.

Also Capital Brief

13 deals

Six Aussie startups that raised $197.4 million this week

Roundup of six Australian funding deals: AutoGrab, Applied EV, Checkbox, Hometime, Factory and On the House, with amounts, investors, and Hometime's past acquisitions and raise history detailed.

Also Startup Daily

5 deals

Airbnb property management platform moves in on $19 million debt and equity deal

Sydney short-stay property manager Hometime has secured $19 million in fresh equity and debt, led by Verona Capital with Commonwealth Bank refinancing; the piece also recounts earlier raises and three rival acquisitions.

Also SmartCompany·Startup Daily

7 deals

Five Aussie startups that raised $95.45 million this week

Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.

Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily

2 deals

Vaccination biotech Vaxxas raises $49 million Series D, cuts C-suite amid broader layoffs

Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.

Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily

Series D+ ~$90m

Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology

Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.

9 deals

Seven ANZ startups that raised $42.8 million this week

Weekly roundup of seven Australian and New Zealand raises totalling $42.8 million, spanning property-investment AI, workforce credentialing, allied-health practice software, conversation analytics, maths learning games, copper processing and holiday-park bookings.

2 deals

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

Vaxxas has finished enrolling 258 volunteers in its Phase I trial of a needle-free HD-MAP avian flu vaccine, funded by a US BARDA contract, with early findings due mid-2025.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au

2 deals

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

Vaxxas has filled its 258-person Phase I trial of a needle-free avian flu vaccine patch, run under a US$28.5 million US government contract; the post also recounts the company's early backing.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au

2 deals

Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas has won the concept stage of BARDA's Patch Forward Prize, earning US$2 million (A$3.2 million) to progress its microarray patch vaccine platform alongside the University of Queensland's BASE facility.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au

Grant $3.2m

Vaxxas Named Stage Winner of United States' BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia

Series D+ $263m

After buying the founder's own business for $43 million, Employment Hero spends another $112m on a Canadian rival

Employment Hero acquires Canada's Humi for $112m and, filings show, paid $43.4m for Ben Thompson's Employment Innovations; the story also recalls its 2023 Series F and investor clash.

Also TechCrunch Venture·Startup Daily

Unnamed stage ~$7.5m

SYNthesis BioVentures Newsletter no. 3

SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.

6 deals

Airbnb management platform banks another $10 million for acquisition ambitions

Hometime, a Sydney platform managing Airbnb properties, has banked $10m from Fifth Estate Asset Management to fund acquisitions, adding two directors; earlier raises and rival takeovers are also recalled.

12 deals

Seven ANZ startups that raised $27.4 million this week

Weekly roundup of seven trans-Tasman raises totalling $27.4 million, headlined by Xefco's $10.5 million round, plus Hometime board appointments and Matrak's China expansion.

Also Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily

9 deals

Nine ANZ startups that raised $60.3 million this week

Roundup of the week's funding news: nine companies across Australia and New Zealand secured investment spanning clean energy, construction logistics, legal tech, coaching, research tools, creator media, medtech and marketing software.

Also Startup Daily·SmartCompany·SmartCompany·SmartCompany·SmartCompany·LaunchVic

Unnamed stage $1.3m

Peeplcoach books $1.3 million raise to expand innovative executive coaching platform

Leadership coaching platform Peeplcoach has raised $1.3 million from backers including Jacinta McDonell and LaunchVic's Alice Anderson Fund, funding local and overseas expansion and taking its total raised beyond $3 million.

Also SmartCompany·Women's Agenda

4 deals

Four Aussie startups that have raised $94.5 million already in January

Roundup of January 2024 funding: Futurerent, Prota Therapeutics, National Renewable Network and Getmee together secured $94.5 million across debt, equity and a government grant, with investor details for each deal.

Series A $32m

Allergies biotech startup Prota Therapeutics innoculated with $32 million in Series A1 raise

Prota Therapeutics, a Melbourne biotech, has secured $32 million in equity and debt ahead of a Phase 3 trial of its peanut allergy therapy, with Singapore's SPRIM Global Investments leading the round.

Also SmartCompany·SmartCompany·SmartCompany·Business News Australia·Forbes Australia

Unnamed stage

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa

Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au

2 deals

Series F News: Employment Hero raises $263 million to take its mission global

Blog announcement of Employment Hero's 263 million Australian dollar Series F, with TCV leading and Insight Partners, AirTree, Seek and OneVentures also participating; the post also unveils the Hero Foundation.

Also Tech Funding News - Australia·TechCrunch Venture·SmartCompany·Startup Daily·Techboard·SmartCompany·Startup Daily·Forbes Australia·Forbes Australia·employmenthero.com·TechCrunch Venture

3 deals

Series F News: Employment Hero raises $263 million to take its mission global

Press release announcing Employment Hero's A$263 million Series F led by TCV, with earlier backers participating, a valuation just under $2 billion, AI-focused global expansion plans, and a look back at the KeyPay acquisition.

Also Tech Funding News - Australia·TechCrunch Venture·SmartCompany·Startup Daily·Techboard·SmartCompany·Startup Daily·Forbes Australia·Forbes Australia·employmenthero.com·TechCrunch Venture

5 deals

From zero to Employment Hero

Sydney HR-and-payroll firm Employment Hero announced a TCV-led Series F reaching unicorn valuation; the profile covers its products, remote workforce and global ambitions, citing rival raises.

Also Tech Funding News - Australia·TechCrunch Venture·SmartCompany·Startup Daily·Techboard·SmartCompany·Startup Daily·Forbes Australia·Forbes Australia·employmenthero.com·employmenthero.com

Something wrong? Tell us